Browse > Home / FDA News / FDA Puts Canada’s Apotex Under Import Alert

FDA Puts Canada’s Apotex Under Import Alert

September 9, 2009

FDA Puts Canada’s Apotex Under Import Alert
The FDA has placed all practised form drug products from two Apotex manufacturing facilities below an import alert following a June 25 warning letter that cited sober capital manufacturing practice (GMP) deficiencies at its Etobicoke, Ontario, plant. The be of consequence to alert involves products manufactured at Ontario facilities in Etobicoke and North York, Canada, FDA spokeswoman Crystal Rice said. The alert is a detention in the absence of physical examination.

Written by Samanta · Filed Under FDA News